Ami Organics Ltd
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
- Market Cap ₹ 4,034 Cr.
- Current Price ₹ 1,094
- High / Low ₹ 1,389 / 882
- Stock P/E 56.6
- Book Value ₹ 171
- Dividend Yield 0.27 %
- ROCE 20.6 %
- ROE 15.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.3% CAGR over last 5 years
- Promoter holding has increased by 0.98% over last quarter.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|
160 | 188 | 239 | 240 | 341 | 520 | 617 | 679 | |
137 | 157 | 196 | 198 | 260 | 415 | 493 | 553 | |
Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 126 |
OPM % | 14% | 16% | 18% | 17% | 24% | 20% | 20% | 19% |
0 | 3 | 0 | 2 | 1 | 3 | 4 | -26 | |
Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 4 |
Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 15 |
Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 81 |
Tax % | 35% | 35% | 34% | 21% | 25% | 21% | 26% | |
12 | 18 | 23 | 27 | 54 | 72 | 83 | 50 | |
EPS in Rs | 80.33 | 123.33 | 22.19 | 26.16 | 17.14 | 19.75 | 22.86 | 12.30 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 37% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 44% |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 23% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 20% |
Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 |
Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 594 |
27 | 44 | 54 | 59 | 137 | 1 | 4 | 101 | |
43 | 54 | 77 | 61 | 110 | 136 | 169 | 236 | |
Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 968 |
28 | 32 | 79 | 85 | 186 | 205 | 259 | 296 | |
CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 92 |
Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 2 |
68 | 91 | 131 | 133 | 225 | 450 | 477 | 578 | |
Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 968 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
29 | 8 | 15 | 27 | 28 | -12 | 66 | |
-19 | -25 | -21 | -24 | -101 | -121 | -33 | |
-7 | 15 | 6 | 0 | 72 | 140 | -12 | |
Net Cash Flow | 3 | -2 | -0 | 3 | -1 | 8 | 20 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
Debtor Days | 83 | 97 | 116 | 86 | 129 | 115 | 136 |
Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 |
Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 |
Cash Conversion Cycle | 11 | 31 | 43 | 88 | 80 | 107 | 111 |
Working Capital Days | 46 | 64 | 68 | 86 | 119 | 141 | 149 |
ROCE % | 38% | 34% | 27% | 33% | 24% | 21% |
Documents
Announcements
- Closure of Trading Window 18h
-
Intimation Under Regulation 30 - Grant Of Patents
2 Mar - The Patent Office, Government of India, has granted Process Patents to Company as per the details attached
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
29 Feb - The Company's Officials will attend 'India Access - Antique''s India Investor Conference' on March 5, 2024 and will meet the investors as per the details …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Feb - The Company's Officials will attend 'Investec India Promoter & Founder Conference 2024' on February 28, 2024 as per the details attached.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
16 Feb - Transcript of the Earnings Conference Call held on February 12, 2024.
Annual reports
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
Leading specialty chemical Company
With a legacy of 14 years, the Company has developed and commercialized over 450 pharma intermediates across 17 key therapeutic areas since inception and NCE, which are being supplied to over 450 customers in India and 50 countries overseas. [1] [2]